Mindfulness Training among Individuals with Parkinson's Disease: Neurobehavioral Effects

Barbara Pickut, Sven Vanneste, Mark A Hirsch, Wim Van Hecke, Eric Kerckhofs, Peter Mariën, Paul M Parizel, David Crosiers, Patrick Cras, Barbara Pickut, Sven Vanneste, Mark A Hirsch, Wim Van Hecke, Eric Kerckhofs, Peter Mariën, Paul M Parizel, David Crosiers, Patrick Cras

Abstract

Objective. To investigate possible neurobehavioral changes secondary to a mindfulness based intervention (MBI) training for individuals living with Parkinson's disease (PD). Background. In the context of complementary medicine, MBIs are increasingly being used for stress reduction and in patient populations coping with chronic illness. The use of alternative and complementary medicine may be higher in patients with chronic conditions such as PD. However, behavioral effects of mindfulness training in PD have not yet been reported in the literature and this points to an unmet need and warrants further examination. Methods. A total of 27 out of 30 PD patients completed a randomized controlled longitudinal trial. Questionnaires and the UPDRS I-IV were obtained at baseline and 8-week follow-up. Results. Significant changes after the MBI were found including a 5.5 point decrease on the UPDRS motor score, an increase of 0.79 points on Parkinson's disease questionnaire (PDQ-39) pain item, and a 3.15 point increase in the Five Facet Mindfulness Questionnaire observe facet. Conclusions. To the best of our knowledge, this is the first quantitative analysis of neurobehavioral effects of MBI in PD.

Figures

Figure 1
Figure 1
Unified Parkinson's Disease Rating Scale (UPDRS) for motor change showed a significant effect for the MBI group.
Figure 2
Figure 2
Five Facet Mindfulness Questionnaire (FFMQ) for observation facet showed a significant effect for the MBI group.
Figure 3
Figure 3
Parkinson's Disease Quality of Life (PDQ-39) showed a marginal significant effect for the MBI group.

References

    1. Simpson J., Lekwuwa G., Crawford T. Predictors of quality of life in people with Parkinson's disease: evidence for both domain specific and general relationships. Disability and Rehabilitation. 2014;36(23):1964–1970. doi: 10.3109/09638288.2014.883442.
    1. Hemmerle A. M., Herman J. P., Seroogy K. B. Stress, depression and Parkinson's disease. Experimental Neurology. 2012;233(1):79–86. doi: 10.1016/j.expneurol.2011.09.035.
    1. Miller M. F., Bellizzi K. M., Sufian M., Ambs A. H., Goldstein M. S., Ballard-Barbash R. Dietary supplement use in individuals living with cancer and other chronic conditions: a population-based study. Journal of the American Dietetic Association. 2008;108(3):483–494. doi: 10.1016/j.jada.2007.12.005.
    1. Wells R. E., Phillips R. S., Schachter S. C., McCarthy E. P. Complementary and alternative medicine use among US adults with common neurological conditions. Journal of Neurology. 2010;257(11):1822–1831. doi: 10.1007/s00415-010-5616-2.
    1. Wang Y., Xie C.-L., Wang W.-W., et al. Epidemiology of complementary and alternative medicine use in patients with Parkinson's disease. Journal of Clinical Neuroscience. 2013;20(8):1062–1067. doi: 10.1016/j.jocn.2012.10.022.
    1. Rajendran P. R., Thompson R. E., Reich S. G. The use of alternative therapies by patients with Parkinson's disease. Neurology. 2001;57(5):790–794. doi: 10.1212/WNL.57.5.790.
    1. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. General Hospital Psychiatry. 1982;4(1):33–47. doi: 10.1016/0163-8343(82)90026-3.
    1. Kabat-Zinn J., Lipworth L., Burney R., Sellers W. Four-year follow-up of a meditation-based program for the self-regulation of chronic pain: treatment outcomes and compliance. Clinical Journal of Pain. 1986;2(3):159–173. doi: 10.1097/00002508-198602030-00004.
    1. Kabat-Zinn J. Mindfulness mediations: health benefits of an ancient Buddhist practice. In: Goleman D., Gurin J., editors. Mind/Body Medicine. Yonkers, NY, USA: Consumer Report Books; 1993. pp. 259–275.
    1. Kabat-Zinn J. Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain and Illness. New York, NY, USA: Delta Publishing; 1990.
    1. Goetz C. G., Tilley B. C., Shaftman S. R., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Disorders. 2008;23(15):2129–2170. doi: 10.1002/mds.22340.
    1. Baer R. A., Smith G. T., Hopkins J., Krietemeyer J., Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006;13(1):27–45. doi: 10.1177/1073191105283504.
    1. Jenkinson C., Fitzpatrick R., Peto V., Greenhall R., Hyman N. The Parkinson's disease questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age and Ageing. 1997;26(5):353–357. doi: 10.1093/ageing/26.5.353.
    1. Levin B. E., Llabre M. M., Weiner W. J. Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory. Journal of Neurology Neurosurgery and Psychiatry. 1988;51(11):1401–1404. doi: 10.1136/jnnp.51.11.1401.
    1. Schrag A., Sampaio C., Counsell N., Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Movement Disorders. 2006;21(8):1200–1207. doi: 10.1002/mds.20914.
    1. Shulman L. M., Gruber-Baldini A. L., Anderson K. E., Fishman P. S., Reich S. G., Weiner W. J. The clinically important difference on the unified parkinson's disease rating scale. Archives of Neurology. 2010;67(1):64–70. doi: 10.1001/archneurol.2009.295.
    1. de la Fuente-Fernández R., Ruth T. J., Sossi V., Schulzer M., Calne D. B., Stoessl A. J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science. 2001;293(5532):1164–1166. doi: 10.1126/science.1060937.
    1. Lidstone S. C., Schulzer M., Dinelle K., et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Archives of General Psychiatry. 2010;67(8):857–865. doi: 10.1001/archgenpsychiatry.2010.88.
    1. Lilja J. L., Lundh L.-G., Josefsson T., Falkenström F. Observing as an essential facet of mindfulness: a comparison of FFMQ patterns in meditating and non-meditating individuals. Mindfulness. 2013;4(3):203–212. doi: 10.1007/s12671-012-0111-8.
    1. Peto V., Jenkinson C., Fitzpatrick R. A. Y. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age and Ageing. 2001;30(4):299–302. doi: 10.1093/ageing/30.4.299.
    1. Gard T., Hölzel B. K., Sack A. T., et al. Pain attenuation through mindfulness is associated with decreased cognitive control and increased sensory processing in the brain. Cerebral Cortex. 2012;22(11):2692–2702. doi: 10.1093/cercor/bhr352.
    1. Ford B. Pain in Parkinson's disease. Movement Disorders. 2010;25(S1):S98–S103. doi: 10.1002/mds.22716.
    1. Hölzel B. K., Carmody J., Vangel M., et al. Mindfulness practice leads to increases in regional brain gray matter density. Psychiatry Research. 2011;191(1):36–43. doi: 10.1016/j.pscychresns.2010.08.006.
    1. Pickut B. A., Van Hecke W., Kerckhofs E., et al. Mindfulness based intervention in Parkinson's disease leads to structural brain changes on MRI: a randomized controlled longitudinal trial. Clinical Neurology and Neurosurgery. 2013;115(12):2419–2425. doi: 10.1016/j.clineuro.2013.10.002.
    1. Ghaffari B. D., Kluger B. Mechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments. Current Neurology and Neuroscience Reports. 2014;14(6):p. 451. doi: 10.1007/s11910-014-0451-y.
    1. Buetow S. A framework for doing person-centred health research. The International Journal of Person Centered Medicine. 2011;1(2):358–361. doi: 10.5750/ijpcm.v1i2.78.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel